Trials / Completed
CompletedNCT00376896
Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers
A Phase IIa Experimental Medicine Study Assessing Alterations in Regional Cerebral Blood Flow by Functional Magnetic Resonance Imaging (fMRI) in Female IBS Patients and Healthy Controls Following Single Doses of GW876008, a Corticotrophin Releasing Factor 1 Receptor Antagonist (CRF1-RA)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a three-period crossover study to compare GW876008 and placebo to see if GW876008 will normalise blood flow responses after different emotional stimuli.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW876008 200mcg | GW876008 |
| DRUG | GW876008 20mcg | GW876008 20mcg |
| OTHER | Placebo | placebo |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2006-09-15
- Last updated
- 2017-05-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00376896. Inclusion in this directory is not an endorsement.